Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DRAGON-06 perioperative sintilimab plus nab-POS with D2 plus PAND for gastric cancer with para-aortic lymph node metastasis
ChiCTR2200061125Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jun 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, paclitaxel, oxaliplatin and tegafur in gastric adenocarcinoma, sponsored by Ruijin Hospital. Primary endpoint: 3-year overall survival. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
sintilimabpaclitaxeloxaliplatintegafur
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2200061125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061125.